David Stukus, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Aquestive Therapeutics
    Topic:
    Nasal epinephrine
    Date added:
    11/04/2025
    Date updated:
    11/04/2025
    Relationship end date:
    06/01/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Genentech
    Topic:
    Anti-IgE therapy for food allergy
    Date added:
    11/04/2025
    Date updated:
    11/04/2025
    Relationship end date:
    06/30/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    DBV Technologies
    Topic:
    Research support peanut immunotherapy
    Date added:
    11/04/2025
    Date updated:
    11/04/2025
  • Attribution:
    Self
    Type of financial relationship:
    Employment
    Ineligible company:
    American College of Allergy Asthma and Immunology
    Topic:
    Current President-Elect
    Date added:
    11/04/2025
    Date updated:
    11/04/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Annals of Allergy, Asthma and Immunology
    Topic:
    Associate Editor
    Date added:
    11/04/2025
    Date updated:
    11/04/2025
Return to Hot Topics in Pediatrics 2026